Journal
MATURITAS
Volume 76, Issue 4, Pages 315-319Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.maturitas.2013.09.009
Keywords
Inflammatory bowel disease; Osteoporosis; Bone mineral density; Fracture; Crohn's disease; Ulcerative colitis
Categories
Funding
- Pfizer Canada
- AbbVie Canada
- Abbott Canada
- Aptalis Pharmaceuticals
- Novartis
- Amgen
- Genzyme
Ask authors/readers for more resources
Inflammatory bowel disease (IBD) is commonly believed to increase the risk of bone mineral loss, leading to osteoporosis and an increased risk of disabling fractures. In this narrative review, we will presenting a summary of the published medical literature in regards to the relationship between IBD and the development of osteoporosis, bone mineral loss, and fractures. We will explore the epidemiology of metabolic bone disease in IBD, focusing on the prevalence and both the general and IBD-specific risk factors for the development of osteoporosis and of fracture in persons with IBD. We will also examine the role of the inflammatory process in IBD promoting excessive bone mineral loss, as well as the role that low body mass, corticosteroid use, diet, and nutrient malabsorption play in contributing to bone disease. Last, we will discuss our recommendation for: screening for osteoporosis in IBD patients, the use of preventative strategies, and therapeutic interventions for treating osteoporosis in persons with IBD. (C) 2013 Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available